Safety and Efficacy of Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Advanced Breast Cancer: A Head-to-Head Comparison of Margetuximab versus Trastuzumab

Detalles Bibliográficos
Autor principal: Zhang, Liyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8186389/
https://www.ncbi.nlm.nih.gov/pubmed/34159226
http://dx.doi.org/10.4103/apjon.apjon-2128
_version_ 1783704946661654528
author Zhang, Liyi
author_facet Zhang, Liyi
author_sort Zhang, Liyi
collection PubMed
description
format Online
Article
Text
id pubmed-8186389
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-81863892021-06-21 Safety and Efficacy of Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Advanced Breast Cancer: A Head-to-Head Comparison of Margetuximab versus Trastuzumab Zhang, Liyi Asia Pac J Oncol Nurs Editorial Wolters Kluwer - Medknow 2021-05-31 /pmc/articles/PMC8186389/ /pubmed/34159226 http://dx.doi.org/10.4103/apjon.apjon-2128 Text en Copyright: © 2021 Ann & Joshua Medical Publishing Co. Ltd https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Editorial
Zhang, Liyi
Safety and Efficacy of Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Advanced Breast Cancer: A Head-to-Head Comparison of Margetuximab versus Trastuzumab
title Safety and Efficacy of Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Advanced Breast Cancer: A Head-to-Head Comparison of Margetuximab versus Trastuzumab
title_full Safety and Efficacy of Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Advanced Breast Cancer: A Head-to-Head Comparison of Margetuximab versus Trastuzumab
title_fullStr Safety and Efficacy of Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Advanced Breast Cancer: A Head-to-Head Comparison of Margetuximab versus Trastuzumab
title_full_unstemmed Safety and Efficacy of Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Advanced Breast Cancer: A Head-to-Head Comparison of Margetuximab versus Trastuzumab
title_short Safety and Efficacy of Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Advanced Breast Cancer: A Head-to-Head Comparison of Margetuximab versus Trastuzumab
title_sort safety and efficacy of human epidermal growth factor receptor 2-targeted therapies in advanced breast cancer: a head-to-head comparison of margetuximab versus trastuzumab
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8186389/
https://www.ncbi.nlm.nih.gov/pubmed/34159226
http://dx.doi.org/10.4103/apjon.apjon-2128
work_keys_str_mv AT zhangliyi safetyandefficacyofhumanepidermalgrowthfactorreceptor2targetedtherapiesinadvancedbreastcanceraheadtoheadcomparisonofmargetuximabversustrastuzumab

Ejemplares similares